Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease

Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG0 个研究点目标入组 110 人开始时间: 2008年3月25日最近更新: 2020年10月26日

试验速览

暂无简介。

•- MS (NCEP ATP III): at least 3 of 5 risk factors (waist circumference in men >102 cm,
•waist circumference in women >88 cm; triglycerides >150 mg/dL; HDL-C in men <40
•mg/dL, HDL-C in women <50 mg/dL; blood pressure >130/85 mmHg or treated
•hypertension; fasting glucose >110 mg/dL or treated diabetes mellitus)
•- Diagnosis of NAFLD defined by the following criteria: alcohol consumption less than
•30 g per day, liver histology compatible with NAFLD (steatosis more than 30% of
•liver parenchyma)
•- Male or female gender
•- Age 18-70 years
•- Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Malignancy within the last five years
•- Chronic liver disease other than NAFLD (viral hepatitis, autoimmune liver disease,
•hemochromatosis, homozygous alpha1-antitrypsin deficiency and Wilson disease)
•- Drug-treated diabetes (insulin or other anti-diabetic drugs), end-organ damage
•due to diabetes (e.g. proliferative retinopathy, renal glomerulosclerosis)
•- BMI >40 kg/m2
•- Inability or contraindications to perform study procedures
•- Participation to other clinical trials in the previous 3 months
•- Mycardial infarction in 6 months prior to enrollment
•- Cerebrovascular events in 6 months prior to enrollment

发起方

Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG